NEO Neogenomics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: NEO

Price (delayed)

$12.3

Market cap

$1.57B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.92

Enterprise value

$1.89B

NeoGenomics, Inc. specializes in cancer genetics testing and information services. The Company provides one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose ...

Highlights
Neogenomics's gross profit has increased by 26% YoY and by 8% QoQ
The company's EPS rose by 23% YoY and by 9% QoQ
The quick ratio has contracted by 19% YoY and by 9% from the previous quarter
The equity is down by 8% year-on-year
Sector: Healthcare
Industry: Diagnostics & Research
Website: https://neogenomics.com/
Peers: BRLI RDNT DGX LH

Key stats

What are the main financial stats of NEO
Market
Shares outstanding
127.55M
Market cap
$1.57B
Enterprise value
$1.89B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.64
Price to sales (P/S)
2.8
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.43
Earnings
Revenue
$551.62M
EBIT
-$130.22M
EBITDA
-$49.17M
Free cash flow
-$64M
Per share
EPS
-$0.92
Free cash flow per share
-$0.51
Book value per share
$7.49
Revenue per share
$4.4
TBVPS
$6.24
Balance sheet
Total assets
$1.7B
Total liabilities
$738.92M
Debt
$609.59M
Equity
$956.19M
Working capital
$489.87M
Liquidity
Debt to equity
0.64
Current ratio
6.16
Quick ratio
5.64
Net debt/EBITDA
-6.52
Margins
EBITDA margin
-8.9%
Gross margin
40%
Net margin
-20.8%
Operating margin
-23.7%
Efficiency
Return on assets
-6.6%
Return on equity
-11.6%
Return on invested capital
-12.4%
Return on capital employed
-8.1%
Return on sales
-23.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NEO stock price

How has the Neogenomics stock price performed over time
Intraday
-1.68%
1 week
1.23%
1 month
-14.82%
1 year
42.03%
YTD
33.12%
QTD
-23.46%

Financial performance

How have Neogenomics's revenue and profit performed over time
Revenue
$551.62M
Gross profit
$220.42M
Operating income
-$130.86M
Net income
-$114.67M
Gross margin
40%
Net margin
-20.8%
Neogenomics's operating margin has increased by 33% YoY and by 11% from the previous quarter
NEO's net margin is up by 31% YoY and by 12% QoQ
Neogenomics's gross profit has increased by 26% YoY and by 8% QoQ
The company's operating income rose by 24% YoY and by 7% QoQ

Growth

What is Neogenomics's growth rate over time

Valuation

What is Neogenomics stock price valuation
NEO P/E details
P/E
N/A
P/B
1.64
P/S
2.8
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.43
The company's EPS rose by 23% YoY and by 9% QoQ
The price to book (P/B) is 60% less than the 5-year quarterly average of 4.1 and 3.5% less than the last 4 quarters average of 1.7
The equity is down by 8% year-on-year
The price to sales (P/S) is 58% lower than the 5-year quarterly average of 6.7 and 7% lower than the last 4 quarters average of 3.0
The revenue rose by 13% YoY and by 4.1% QoQ

Efficiency

How efficient is Neogenomics business performance
The company's return on sales rose by 26% YoY and by 11% QoQ
The return on assets rose by 16% year-on-year and by 8% since the previous quarter
The return on equity has increased by 14% year-on-year and by 7% since the previous quarter
NEO's ROIC is up by 13% year-on-year and by 6% since the previous quarter

Dividends

What is NEO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NEO.

Financial health

How did Neogenomics financials performed over time
The total assets is 129% greater than the total liabilities
The quick ratio has contracted by 19% YoY and by 9% from the previous quarter
NEO's current ratio is down by 18% YoY and by 9% from the previous quarter
NEO's debt is 36% lower than its equity
The equity is down by 8% year-on-year
The debt to equity rose by 8% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.